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Abstract
Virus replication efficiency is influenced by two conflicting factors, kinetics of the cellular interferon (IFN) response and
induction of an antiviral state versus speed of virus replication and virus-induced inhibition of the IFN response.
Disablement of a virus’s capacity to circumvent the IFN response enables both basic research and various practical
applications. However, such IFN-sensitive viruses can be difficult to grow to high-titer in cells that produce and respond to
IFN. The current default option for growing IFN-sensitive viruses is restricted to a limited selection of cell-lines (e.g. Vero
cells) that have lost their ability to produce IFN. This study demonstrates that supplementing tissue-culture medium with an
IFN inhibitor provides a simple, effective and flexible approach to increase the growth of IFN-sensitive viruses in a cell-line of
choice. We report that IFN inhibitors targeting components of the IFN response (TBK1, IKK2, JAK1) significantly increased
virus replication. More specifically, the JAK1/2 inhibitor Ruxolitinib enhances the growth of viruses that are sensitive to IFN
due to (i) loss of function of the viral IFN antagonist (due to mutation or species-specific constraints) or (ii) mutations/host
cell constraints that slow virus spread such that it can be controlled by the IFN response. This was demonstrated for a
variety of viruses, including, viruses with disabled IFN antagonists that represent live-attenuated vaccine candidates
(Respiratory Syncytial Virus (RSV), Influenza Virus), traditionally attenuated vaccine strains (Measles, Mumps) and a slow-
growing wild-type virus (RSV). In conclusion, supplementing tissue culture-medium with an IFN inhibitor to increase the
growth of IFN-sensitive viruses in a cell-line of choice represents an approach, which is broadly applicable to research
investigating the importance of the IFN response in controlling virus infections and has utility in a number of practical
applications including vaccine and oncolytic virus production, virus diagnostics and techniques to isolate newly emerging
viruses.
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Introduction
Virus infection triggers the cellular interferon (IFN) response to
produce Type 1 IFN’s alpha and beta (IFNa/b). Secreted IFNa/b
can stimulate the JAK-STAT pathway in an autocrine or
paracrine manner to activate hundreds of IFN-stimulated genes
(ISGs), many of which have antiviral activities that elicit an
antiviral state [1]. Although the IFN system constitutes a powerful
antiviral response, it rarely works to full capacity because virus-
encoded IFN antagonists circumvent it [1]. Manipulation of a
virus’s capacity to circumvent the IFN response enables both basic
research and various practical applications. For example, genetic
engineering has facilitated rational design of live-attenuated
vaccines, where a common approach is to disable a virus’s IFN
antagonist thereby restricting its ability to circumvent the IFN
response [2–8]. The rationale being that IFN antagonists are
typically dispensable for virus replication in cell culture but are
required for virulence in vivo and thus the vaccine will mimic
natural infection in stimulating the immune system but without
causing disease. Knockout of viral IFN antagonists is also a
method of engineering viruses to specifically target cancer cells for
oncolytic virotherapy [9,10]. The rationale exploits the fact that
tumorigenesis can result in impairment of innate immune
responses, therefore viruses that no longer counteract the IFN
response are often able to propagate in tumor cells but not normal
cells and thus mediate tumor-specific killing.
Despite the advantages of disabling a virus’s IFN antagonist, it
can be difficult to grow such IFN-sensitive viruses to high-titer in
tissue culture cells that produce and respond to IFN [11]. The
current default option for growing such IFN-sensitive viruses is
largely restricted to a very limited selection of cell-lines (e.g. Vero
cells) that have lost their ability to produce IFN [12,13]. However,
many viruses do not grow efficiently in these cells, presumably due
to other host cell constraints on virus replication [11]. To tackle
this limitation, we have previously engineered cell-lines to no
longer produce or respond to IFN by constitutive expression of
Npro from Bovine Viral Diarrhea Virus (BVDV-Npro) which
blocks IFN induction by targeting IRF3 for proteasome-mediated
degradation [14] or constitutive expression of the parainfluenza
type 5 virus V protein (PIV5-V), which blocks IFN signaling by
targeting STAT1 for proteasome-mediated degradation [11]. In
these engineered IFN incompetent cells vaccine candidate viruses
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and slow-growing wild-type viruses formed bigger plaques and
grew to increased titers [11], demonstrating the potential use of
these cell-lines for the applications described above. In addition
such IFN incompetent cell-lines can be useful in virus diagnostics,
isolation of newly emerging viruses and basic research [11].
However, genetically engineering cell-lines is time consuming and
their use creates regulatory problems for vaccine manufacturers.
We hypothesize that small molecule inhibitors of the IFN response
would offer a simple and flexible solution, as an effective inhibitor
could easily supplement the tissue culture medium of cell-lines of
choice.
Materials and Methods
Inhibitors, viruses and cells
Inhibitors of the IFN response (BX795, MRT68844,
MRT67307, TPCA-1, Cyt387, AZD1480, Ruxolitinib, Tofaciti-
nib) were prepared as 10 mM stocks in dimethyl sulfoxide
(DMSO) and used at the indicated concentrations. Inhibitors
were purchased from Selleck Chemicals except MRT68844 and
MRT67307, which were gifts of MRC-Technology and Philip
Cohen (University of Dundee) respectively. Cell-lines derived from
a variety of mammalian species were utilized: human (A549 and
MRC5) monkey (Vero), mouse (BalB/C), rabbit (RK13), dog
(MDCK) and pig (PKIBRS2). These cells were obtained from the
European Collection of Cell Cultures (ECACC) with the exception
of the PKIBRS2 cells, which were obtained from the Institute of
Animal Health (UK) [15]. Derivatives of the A549 cells were used;
A549/pr(IFN-b).GFP and A549/pr(ISRE).GFP reporter cell-lines
which contain a eGFP (enhanced Green Fluorescent Protein) gene
under the control of the IFN-b promoter or an IFN stimulated
response element (ISRE) respectively [16], A549/BVDV-NPro
and A549/PIV5-V cell-lines which constitutively express the IFN
antagonists BVDV-Npro and PIV5-V respectively [14,17]. A
derivative of the MRC5 cell-line that constitutively expresses
PIV5-V (MRC5/PIV5-V) was also used [11]. All cell-lines were
grown in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% v/v fetal bovine serum. Viruses used in the
study were Bunyamwera wildtype (BUN-WT) and a DNSs
derivative (BUNDNSs) [18], Respiratory Syncytial Virus (RSV)
and DNS1 or DNS2 derivatives [7,19], Influenza (A/PR/8/34)
and DNS1 derivative [20], Measles (MeV) Edmonson and Mumps
(MuV) Enders vaccine strains (NIBSC), and a VDC derivative of
PIV5 (PIV5VDC) [21]. All viruses were grown and titrated under
appropriate conditions.
IFN induction and signaling reporter assays
The A549/pr(IFN-b).GFP and A549/pr(ISRE).GFP reporter
cell-lines were used to test the effect of IFN inhibitors on IFN
induction or IFN signaling. A549/pr(IFN-b).GFP were seeded into
a 96 well plate and media supplemented with a TBK1 inhibitor
(BX795, MRT6884 or MRT67307) or the IKK2 inhibitor
(TPCA-1) at the indicated concentrations or equivalent volumes
of DMSO. Two hours post-inhibitor treatment cells were infected
with a stock of PIV5VDC rich in defective interfering particles
(DIs) to optimally activate the IFN induction pathway and
expression of GFP under the control of the IFN-b promoter
[16]. Eighteen hours post-infection GFP expression was measured
using a Tecan Infinite plate reader at excitation/emission 488/
518 nm. Cells were fixed with 5% (v/v) formaldehyde and stained
with crystal violet staining (0.015% w/v) to monitor cellular
cytotoxicity. A549/pr(ISRE).GFP were similarly seeded and
media supplemented with a JAK1 inhibitor (Cty387, AZD1480,
Ruxolitinib or Tofacitinib) at the indicated concentrations or
equivalent volumes of DMSO. Two hours post-inhibitor addition
cell supernatant was supplemented with 104 units/ml of purified a-
IFN (Roferon, NHS) to activate the IFN signaling pathway and
GFP expression from the IFN response (ISRE) promoter. Forty-
eight hours post-IFN stimulation GFP expression and cellular
cytotoxicity were measured as described above. Each assay was
conducted in triplicate and the mean and standard deviation
(StDev) determined.
Virus plaque assays and growth kinetics
Standard plaque assays were conducted in the appropriate cells
using a 0.6% (w/v) avicell overlay [22] and fixed with 5% (v/v)
formaldehyde at the indicated times. Plaques were visualized by
crystal violet staining (0.015% w/v) or immunostaining using the
following primary antibodies; anti-Bunyamwera N protein (Kind
gift of Richard Elliott, University of Glasgow), anti-RSV F protein
(Serotech), anti-Influenza X31 antibody (Diagnostic Scotland),
anti-MeV NP (Abcam) and anti-MuV NP (Abcam) followed by the
appropriate alkaline phosphatase conjugated secondary antibody
and SIGMA FAST BCIP/NBT substrate. Virus growth kinetics
was preformed in A549, A549/BVDV-Npro, A549/PIV5-V,
MRC5, MRC5/PIV5-V and Vero cells infected with BUNDNSs
at a 0.001 MOI and grown in the presence or absence of inhibitor
at the indicated concentrations. At various times post infection the
amount of infectious virus in the culture medium was estimated
(pfu/ml) by plaque assays on Vero cells. All experiments were
performed at least in duplicate.
Results and Discussion
Eight small molecules that have previously been described to
inhibit the cellular IFN response were obtained; four inhibitors
that target components of the IFN induction pathway: TBK1
inhibitors BX795, MRT68844, MRT67307 [23,24] and the IKK-
2 inhibitor TPCA-1 [25], plus four inhibitors that target JAK1 a
component of the IFN signaling pathway: Cyt387, AZD1480,
Ruxolitinib and Tofacitinib [26–29]. We verified the ability of
these molecules to inhibit IFN induction or IFN signaling using
two A549 reporter cell-lines in which a GFP gene is placed under
the control of either the IFN-b promoter (A549/pr(IFN-b).GFP)
or an ISRE promoter (A549/pr(ISRE).GFP) [16]. The four
inhibitors targeting components of the IFN induction pathway
(BX795, MRT68844, MRT67307 and TPCA-1) were tested using
the A549/pr(IFN-b).GFP reporter cell-line. The IFN induction
pathway and hence GFP expression was optimally activated in this
cell-line by infection with a PIV-5/VDC virus stock rich in DIs
(Fig. 1A). Inhibitors that target components of the IFN induction
pathway would be expected to block GFP expression. The IKK-2
inhibitor TPCA-1 demonstrated a significant block to GFP
expression, while the TBK1 inhibitor BX795 showed a weak
effect at a concentration of 4 mM, however no activity was
observed for the MRT68844 and MRT67307 inhibitors (Fig. 1A).
The JAK1 inhibitors (Cyt387, AZD1480, Ruxolitinib and
Tofacitinib) were similarly tested in the A549/pr(ISRE).GFP
reporter cell-line following activation of the IFN signaling pathway
using purified IFN (Fig. 1B). All four JAK1 inhibitors blocked GFP
expression in the (A549/pr(ISRE).GFP reporter cell-line, however
Ruxolitinib had the greatest effect (Fig. 1B). Therefore six of the
molecules tested (TPCA-1, BX795, Cyt387, AZD1480, Ruxoliti-
nib and Tofacitinib) inhibited the IFN induction or IFN signaling
pathway as expected without causing cellular cytotoxicity (data not
shown), however the two MRT molecules (MRT68844 and
MRT67307) did not show any activity in this cell-based assay.
IFN Inhibitors Virus Replication
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Effect of the inhibitors on viral plaque formation was examined
using A549 cells infected with recombinant Bunyamwera virus
(BUNDNSs), in which the NSs IFN antagonist has been
inactivated rendering the virus IFN sensitive [18]. BUNDNSs
represents a convenient test virus and pathogenic members of the
Bunyaviridae family are being developed as attenuated vaccines
via NSs knockout [5,6]. Standard plaque assays were performed
and fixed 2 days post-infection. A dose-dependent increase in
plaque size was observed for all inhibitors with the exception of
MRT68844 and MRT67307, which had no effect (Fig. 2). The
lack of phenotypic effect observed for the MRT68844 and
MRT67307 inhibitors corresponds to their inability to inhibit
the IFN induction cascade in our cell-based reporter assay
(Fig. 1A). The JAK1/2 inhibitor Ruxolitinib had the most
substantial effect; at $1 mM plaque formation was equivalent to
that observed in A549/PIV5-V cells. The A549/PIV5-V cell-line
constitutively expresses the PIV5 IFN antagonist V, which blocks
IFN signaling by targeting STAT1 for proteasome-mediated
degradation. Growth of IFN-sensitive viruses is boosted in this cell-
line [11] and hence it is used here as a control for assessing the
effect of inhibitor treatment.
The six effective inhibitors were used to examine their effect on
BUNDNSs growth kinetics and all six inhibitors significantly
improved virus titers (Fig. 2b). At 48 hours post-infection titers of
BUNDNSs were ,5logs greater in the presence of Ruxolitinib,
Tofacitinib, AZD1480 and TPCA-1 compared to DMSO
treatment. The maximum titer achieved was equivalent to that
reached in A549/PIV5-V cells, although for reasons that currently
are unclear in the A549/PIV5-V cells the maximum titer was
achieved slightly earlier at 36 hours post-infection. It is also
noteworthy that the TBK1 and IKK2 inhibitors exhibited a more
pronounced effect on boosting viral growth than inhibition of the
IFN induction pathway (Fig. 1 and 2). One explanation for this
discrepancy maybe that these inhibitors target other cellular
components that are not accounted for in the A549/pr(IFN-
b).GFP reporter cell-line assay but which have a synergistic effect
on boosting virus growth. In conclusion, supplementing cell
culture medium with a variety of IFN inhibitors that target
different components of the IFN response (TBK1, IKK2, JAK1)
significantly boosts replication and yield of an IFN-sensitive
Bunyamwera virus.
We next sought to determine if two inhibitors targeting different
components of the IFN response could further boost BUNDNSs
Figure 1. Verification of IFN inhibitors ability to block IFN induction or IFN signaling. (a) Small molecules reported to inhibit the IKK2
(TPCA-1) and TBK1 (BX795, MRT6884, MRT6707) components of the IFN induction pathway were tested using the A549/pr(IFN-b).GFP reporter cell-
line which contains an eGFP gene under control of the IFN-b promoter. The IFN induction pathway and hence GFP expression was activated by
infection with a DI rich stock of PIV5VDC. Effect of inhibitors at various concentrations was measured by monitoring fluorescence at 18 hours post-
infection. (b) Small molecules reported to inhibit the JAK1 (Cyt387, AZD1480, Ruxolitinib, Tofacitinib) component of the IFN signaling pathway were
tested using the A549/pr(ISRE).GFP reporter cell-line which contains an eGFP gene under control of an ISRE promoter. The IFN signaling pathway and
hence GFP expression was activated by supplementing the cell supernatant with purified IFN. Effect of inhibitors at various concentrations was
measured by monitoring fluorescence at 48 hours post IFN stimulation.
doi:10.1371/journal.pone.0112014.g001
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growth if used in combination with each other or to supplement
the medium of infected A549/PIV5-V cells. The IKK-2 inhibitor
TPCA-1 and JAK1/2 inhibitor Ruxolitinib were tested. However
combinations resulted in no further increases in plaque size in
A549 cells and in fact a small decrease in plaque size was observed
when the inhibitors were used in combination compared to
Ruxolitinib or PIV5-V expressing cells alone (Fig. 3a). One
possible explanation for the small decrease in plaque size might
be that low levels of cellular cytotoxicity occur in the presence of a
combination of inhibitors. The lack of an increase in plaque size
suggests that a combination of inhibitors would not lead to
significant differences in virus growth kinetics or yield, therefore
experiments to test this were not performed. In Vero cells, the two
inhibitors, singularly or in combination, did not effect BUNDNSs
plaque size formation (Fig. 3a). However it was of note that
BUNDNSs plaque development was significantly slower in Vero
cells compared to A549/PIV5-V cells or to A549 cells supple-
mented with each inhibitor (Fig. 3a). Growth curves also
demonstrated that BUNDNSs replicated more quickly in A549
cells than Vero cells; at 48 hours post-infection virus titer was
significantly higher (,2log) in A549 cells cultured in the presence
of inhibitor or in A549/PIV5-V cells compared to Vero cells
(Fig. 3b). The approximate equivalent titer in Vero cells was
achieved ,24 hours later (Fig. 3b). These data support our
previous observations suggesting that the default Vero cell-line
may not always be the best option to produce the maximum virus
yield in the minimum time, presumably due to host cell constraints
other than the IFN response that contribute to restricted virus
replication [11]. Instead we show that simply supplementing tissue
culture media with an IFN inhibitor provides a simple, effective
and flexible alternative to facilitate the growth of IFN-sensitive
viruses in a cell-line of choice.
Figure 2. Effect of a panel of IFN inhibitors on BUNDNSs virus
growth in A549 cells. The inhibitor panel consists of small molecules
that target the IKK2 (TPCA-1) and TBK1 (BX795, MRT6884, MRT6707)
components of the IFN induction pathway and JAK1 (Cyt387, AZD1480,
Ruxolitinib, Tofacitinib) a component of the IFN signaling pathway.
Effect of the inhibitors was compared with A549 cells constitutively
expressing viral IFN antagonists that block IFN production (BVDV-Npro)
or IFN signaling (PIV5-V). (a) Effect of various inhibitor concentrations on
plaque size formation. Plaques were visualized 2 days post-infection by
crystal violet staining. (b) Virus growth monitored over time in presence
of 2 mM inhibitor or the equivalent volume of DMSO and pfu/ml
determined from reserved supernatants by titration in Vero cells.
doi:10.1371/journal.pone.0112014.g002
Figure 3. Effect of a combination of different IFN inhibitors on
BUNDNSs growth in A549 and Vero cells. (a) BUNDNSs plaque
formation in A549 or Vero cells in the presence of TPCA-1 or Ruxolitinib
(RUX), TPCA-1 and RUX in combination with each other or PIV5-V. Each
inhibitor was used at 2 mM and compared to the equivalent volume of
DMSO when the inhibitors were used in combination. Plaque size
formation was assessed 42 hours post infection (p.i) in A549 cells and
both 42 and 72 hours p.i. in Vero cells. Plaques were visualized by
crystal violet staining. (b) BUNDNSs virus growth monitored over time in
A549 cells in the presence of 4 mM RUX, the equivalent volume of
DMSO or PIV5-V and Vero cells. Supernatants were reserved and pfu/ml
determined by titration in Vero cells.
doi:10.1371/journal.pone.0112014.g003
IFN Inhibitors Virus Replication
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A limited number of cell-lines have regulatory approval for
vaccine manufacture e.g. MRC5 [30]. Therefore we extended our
study to demonstrate that in MRC5 cells, BUNDNSs plaque size
was increased in the presence of Ruxolitinib and plaques formed
were equivalent in size to those in MRC5/PIV5-V cells (Fig. 4a).
We further extended our study to examine the effect of Ruxolitinib
on plaque size formation in cell-lines derived from different
mammalian species using BUNDNSs and wild-type Bunyamwera
virus (BUN-WT) as test viruses. As expected, Ruxolitinib increased
BUNDNSs plaque size to varying degrees in all cell-lines tested
(Fig. 4). Ruxolitinib did not significantly affect BUN-WT plaque
size in either MRC5 or A549 cells (Fig. 4a). This was not
surprising since BUN-WT virus encodes a functional IFN
antagonist and can infect humans. However, in mouse- and
rabbit-derived cell-lines, BUN-WT formed only small plaques 2
days post-infection and Ruxolitinib moderately increased plaque
size (Fig. 4b). More strikingly, BUN-WT formed tiny plaques in
dog- and pig-derived cell-lines (Fig. 4b) but Ruxolitinib signifi-
cantly increased BUN-WT plaque size in these cells (Fig. 4b). One
explanation for this data is that the Bunyamwera virus NSs protein
is non-functional in dog- and pig-derived cell-lines, suggesting
possible species constraints on IFN antagonist function. These
results illustrate that use of IFN inhibitors may offer a general
approach to quickly initiate studies to investigate species-specific
constraints on viral IFN antagonist function, and hence presum-
ably on virus host range. The data also support the concept that
supplementing cell-culture medium with IFN inhibitors provides a
flexible method to improve techniques to isolate emerging viruses
by aiding virus growth in a range of cell-lines derived from
different species.
Respiratory Syncytial Virus (RSV) and Influenza are examples
of viruses currently being developed as IFN-sensitive attenuated
vaccine candidates [2–4,7,8]. Deletion of RSV IFN antagonists
NS1 and NS2 impairs virus growth in MRC5 cells (Fig. 5a) but
Ruxolitinib increased plaque size formation in both viruses to that
equivalent of MRC5/PIV5-V cells (Fig. 5a). Therefore IFN
inhibitors could be useful in the industrial production of IFN-
sensitive attenuated RSV vaccine candidates particularly in light of
our previous data demonstrating that higher yields of RSV can be
achieved in human-derived PIV5-V expressing cells rather than
Vero cells [11]. In addition the ability to grow RSV in a cell-line
other than Vero cells could be important for vaccine production
because virions produced from Vero cells contain a C-terminally
truncated 55KDa G glycoprotein which is responsible for a
significant reduction (600-fold) in initial infectivity particularly in
primary respiratory epithelial target cells [31]. Therefore the use of
IFN inhibitors to facilitate the production of candidate RSV
vaccines in a cell-line other than Veros would not only increase
virus yield but could also reduce the required vaccine inoculum.
Plaque size of wild-type (WT) RSV also increased in the presence
of Ruxolitinib (Fig. 5a). This supports our previous observation
that inhibiting the IFN response aids the growth of some
intrinsically slow growing viruses [11] and could potentially
facilitate more rapid isolation of viruses from clinical viral samples.
Wild-type influenza (A/PR/8/34) virus plaque size was not
increased by Ruxolitinib, presumably because Influenza virus is a
fast growing virus that encodes a powerful IFN antagonist the NS1
protein (Fig. 5b). However, Ruxolitinib significantly increased the
plaque size of a recombinant A/PR/8/34 DNS1 virus that does
not encode NS1 (Fig. 5b).
We also tested two traditional vaccine strains, measles (MeV)
Edmonson and the Mumps (MuV) Enders, which have been
generated empirically using nonsystematic attenuation methods
[32,33]. Plaque size of the MeV and MuV vaccine strains were
significantly increased in the presence of Ruxolitinib (Fig. 5c).
MeV vaccine strains contain attenuating mutations in the P, V and
C proteins that contribute to IFN antagonism [34]. However,
MuV Enders contains a functional V protein IFN antagonist [35],
providing evidence that IFN inhibitors can boost the yield of
viruses with reduced replication rates due to attenuating mutations
that do not affect viral IFN antagonists, presumably due to the
balance between kinetics of virus replication and induction of the
IFN response. This is in agreement with our previous work, which
demonstrated that RSV viruses with mutations in G and SH
proteins whose functions are not directly relevant to the IFN
response grew better in PIV5-V expressing cells [11].
We have demonstrated that several IFN inhibitors increased
virus growth in vitro. In the initial plaque formation screen the
JAK1/2 inhibitor Ruxolitinib was the most effective and hence
was taken forward for further study. Moreover, all the results
obtained for Ruxolitinib were essentially mirrored with the IKK2
inhibitor TPCA-1 (data not shown). The plaque assays and growth
curves performed required incubation with the inhibitor for
multiple days. To ensure our results were not affected by loss of
activity of the drug, we used the A549/pr(IFN-b).GFP and A549/
pr(ISRE)GFP reporter cell-lines to measure the activity of the drug
over time; confirming that the inhibitory effect of both Ruxolitinib
and TPCA-1 was stable up to at least 7 days in tissue-culture
(Fig. 6).
These results provide proof of principle that supplementing
tissue-culture medium with IFN inhibitors provides a simple,
effective and flexible approach to enhance virus growth in
Figure 4. Effect of Ruxolitinib (RUX) on BUNDNSs and BUN-WT
(wildtype) plaque formation in cell-lines derived from different
mammalian species. (a) Human cell-lines A549 and MRC5 and their
derivatives constitutively expressing the viral IFN antagonist PIV5-V and
(b) cell-lines derived from mouse (BalB/C), Rabbit (RK13), Dog (MDCK)
and Pig (PKIBRS2). RUX was used at 4 mM and compared with an
equivalent volume of DMSO. Plaques were fixed on the day indicated
and visualized by immunostaining with an anti-Bunyamwera N protein
antibody.
doi:10.1371/journal.pone.0112014.g004
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cell-lines of choice. IFN inhibitors targeting different components
of the IFN response (TBK1, IKK2 and JAK1) significantly
increased replication and yield of a variety of viruses; including
examples of potential vaccine candidates with disabled IFN
antagonists (RSV, Influenza), traditionally attenuated vaccine
strains (MeV, MuV) and wild-type viruses (RSV, Bunyamwera). In
Figure 5. Effect of Ruxolitinib (RUX) on plaque formation of a selection of viruses. (a) RSV WT and derivatives with deleted IFN antagonists
NS1 (DNS1) and NS2 (DNS2). RSV plaques were grown in the MRC5 cell-line or derivative constitutively expressing PIV5-V, fixed on the days indicated
and visualized by immunostaining with an anti-RSV F protein antibody. (b) Influenza (A/PR/8/34) WT and derivative with a deleted IFN antagonist NS1
(DNS1). Influenza plaques were grown in the MDCK cell-line, fixed on the days indicated and visualized by immunostaining with an anti-influenza X31
antibody. (c) MeV Edmonston (Edm) and MuV Enders (End) live-attenuated vaccine strains. MeV and MuV plaques were grown in MRC5 cell-line or
derivative constitutively expressing PIV5-V fixed on the day indicated and visualized by immunostaining with an anti-MeV NP or anti-MuV NP
antibodies respectively. RUX was used at 4 mM and compared with the equivalent volume of DMSO.
doi:10.1371/journal.pone.0112014.g005
Figure 6. Inhibitory activity of Ruxolitinib and TPCA-1 is stable over time in cell culture. A549 cells cultured at 37uC in the presence of
media supplemented with 4 mM Ruxolitinib, 4 mM TPCA-1 or the equivalent volume of DMSO. Cell culture medium was sampled over time and stored
at 280uC prior to testing the inhibitory activity of the cell culture medium containing (a) TPCA-1 in the A549/pr(IFN-b).GFP reporter cell-line or (b)
Ruxolitinib in the A549/pr(ISRE).GFP reporter cell-line. The reporter assays were conducted using the standard method, briefly the A549/pr(IFN-b).GFP
cell-line was activated by PIV5VDC infection and GFP measured 18 hours post-infection and the A549/pr(ISRE).GFP cell-line activated with purified IFN
and GFP measured 48 hours post-IFN treatment.
doi:10.1371/journal.pone.0112014.g006
IFN Inhibitors Virus Replication
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addition JAK1 inhibitors have recently been shown to enhance the
growth of oncolytic vesicular stomatitis virus (VSV) in cancer cells
resistant to oncolysis [36]. All the viruses tested have an RNA
genome, however it is reasonable to predict that IFN inhibitors
would also be beneficial in improving the growth of IFN-sensitive
viruses harboring a DNA genome. Thus, the use of IFN inhibitors
to enhance virus growth in vitro can facilitate both basic research
and a number of practical applications including vaccine and
oncolytic virus manufacture, virus diagnostics and techniques to
isolate newly emerging viruses. Potential drawbacks for the use of
inhibitors for some or all of the suggested applications are (i) the
cost of the inhibitor and (ii) the harvested virus stocks will contain
the inhibitor which may affect experiments to address both basic
science questions and regulatory problems for medical applications
in humans, although in this latter regard it is noteworthy that
Ruxolitinib is approved for clinical treatment of myelofibrosis [37].
Purification of virus stocks would eliminate the second issue, and
regardless of inhibitor presence, should always be considered for
fundamental studies, as a variety of different cytokines that are
induced and secreted in response to virus infection will be present
in unpurified virus stocks. Since inhibitors such as Ruxolitinib can
be administered in vivo, they may also prove useful in studies
designed to investigate the importance of the IFN response in
controlling virus infections in animal models.
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